HZNP Horizon Pharma plc

13.96
+0.31  (2%)
Previous Close 13.65
Open 13.71
Price To book 2.29
Market Cap 2287845810
Shares 163,885,803
Volume 260,643
Short Ratio 6.88
Av. Daily Volume 2,671,866

SEC filingsSee all SEC filings

  1. CT ORDER - Confidential treatment order 171195687
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 171178235
  3. 8-K - Current report 171178214
  4. 8-K - Current report 171149053
  5. CT ORDER - Confidential treatment order 171110385

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data released December 8, 2016 - primary endpoint not met.
ACTIMMUNE
Friedreich's Ataxia (FA)

Latest News

  1. ETFs with exposure to Horizon Pharma Plc : November 13, 2017
  2. Horizon Pharma Plc :HZNP-US: Earnings Analysis: Q3, 2017 By the Numbers : November 10, 2017
  3. Horizon Pharma plc Selected as One of Chicago’s Top Workplaces by the Chicago Tribune
  4. See what the IHS Markit Score report has to say about Horizon Pharma PLC.
  5. Horizon Pharma Plc breached its 50 day moving average in a Bearish Manner : HZNP-US : November 10, 2017
  6. Edited Transcript of HZNP earnings conference call or presentation 6-Nov-17 1:00pm GMT
  7. Horizon Pharma plc Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
  8. Horizon Pharma (HZNP) Tops Q3 Earnings & Sales, Ups View
  9. Horizon Pharma plc Presents New Data at 2017 ACR/ARHP Annual Meeting, Advances Clinical Understanding of KRYSTEXXA® (pegloticase injection) in Adults with Uncontrolled Gout
  10. Horizon Shares Rise on Q3 Results, Guidance -- Biotech Movers
  11. Horizon (HZNP) Tops Q3 Earnings, Shares Up
  12. Horizon Pharma reports 3Q loss
  13. Horizon Pharma plc Announces Third-Quarter and Year-to-Date 2017 Results
  14. Horizon Pharma Plc to Host Earnings Call
  15. How Financially Strong Is Horizon Pharma Public Limited Company (HZNP)?
  16. Horizon Pharma plc Presents Results from an Open-Label Study on the Use of PROCYSBI® (cysteamine bitartrate) Delayed-Release Capsules in Treatment-Naïve Children Younger than 6 Years of Age
  17. Horizon Pharma plc Announces Poster Presentation on KRYSTEXXA® (pegloticase injection) at the American Society of Nephrology Kidney Week 2017
  18. Key Predictions for Q3 Earnings Reports of MYL, HZNP & KERX
  19. Horizon Pharma plc to Participate in Investor Conferences in November
  20. Horizon Pharma (HZNP) Q3 Earnings: A Disappointment in Store? (revised)

SEC Filings

  1. CT ORDER - Confidential treatment order 171195687
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 171178235
  3. 8-K - Current report 171178214
  4. 8-K - Current report 171149053
  5. CT ORDER - Confidential treatment order 171110385
  6. 10-Q/A [Amend] - Quarterly report [Sections 13 or 15(d)] 171108459
  7. S-8 - Securities to be offered to employees in employee benefit plans 171066777
  8. 8-K - Current report 171066384
  9. 10-Q - Quarterly report [Sections 13 or 15(d)] 171009980
  10. 8-K - Current report 171009965